Paroxysmal nocturnal hemoglobinuria, or PNH, is a rare disease characterized by hemolysis, thrombosis, and bone marrow failure. Intravenous anti-C5 monoclonal antibodies are the standard treatment; however, many patients remain anemic, mainly because of ongoing activation of extravascular hemolysis mediated by macrophages ingesting C3 fragment-coated red cells. Now, two phase 3 trials have evaluated the efficacy and safety of iptacopan, an oral complement factor B inhibitor, in PNH. Research findings are summarized in a new Quick Take video. https://lnkd.in/eZAWEA46 Read the related Original Article by Régis Peffault de Latour, M.D., et al.: https://nej.md/48QKlcU #ClinicalTrials #MedicalResearch
NEJM Group’s Post
More Relevant Posts
-
👏Amazing Solution. 👊With you from day 1. 💪We changed Dialysis CVC protocols given to the patients better outcome. 🌊The Solutions to save and protect your CVC #Medivalsrl #Tauropharm #Infectionprevention
🎉 2024 marks the 15th anniversary of TauroLock™-U25.000 – the only antimicrobial lock solution that contains urokinase (along with taurolidine and 4 % citrate). It was developed particularly for patients with patency issues: The active ingredient urokinase is fibrinolytic and breaks up blood clotting in early stages. 🛡️ For the strongest prophylaxis against catheter-related infection and thrombosis, we recommend the 2+1 protocol: 2x weekly TauroLock™-HEP500, 1x weekly TauroLock™-U25.000. This formula has proven safe, effective, and cost-efficient in several clinical studies. (1-4) #tauropharm #taurolock #antimicrobial #infectionprevention #dialysis #thrombosis 1) Al-Ali et al. Nephrol Dial Transplant 2018. DOI: 10.1093/ndt/gfx187 2) Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026 3) Bonkain et al. PLoS One 2021. DOI: 10.1371/journal.pone.0251793 4) Fontseré et al. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.02.004
-
-
🎉 2024 marks the 15th anniversary of TauroLock™-U25.000 – the only antimicrobial lock solution that contains urokinase (along with taurolidine and 4 % citrate). It was developed particularly for patients with patency issues: The active ingredient urokinase is fibrinolytic and breaks up blood clotting in early stages. 🛡️ For the strongest prophylaxis against catheter-related infection and thrombosis, we recommend the 2+1 protocol: 2x weekly TauroLock™-HEP500, 1x weekly TauroLock™-U25.000. This formula has proven safe, effective, and cost-efficient in several clinical studies. (1-4) #tauropharm #taurolock #antimicrobial #infectionprevention #dialysis #thrombosis 1) Al-Ali et al. Nephrol Dial Transplant 2018. DOI: 10.1093/ndt/gfx187 2) Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026 3) Bonkain et al. PLoS One 2021. DOI: 10.1371/journal.pone.0251793 4) Fontseré et al. Nefrologia (Engl Ed) 2021. DOI: 10.1016/j.nefro.2021.02.004
-
-
Neuro, Vascular & Interventional Radiologist, NRI Academy of medical sciences , Guntur
42 year old female with history of rheumatoid arthritis and hypertension presented with rest pain in bilateral lower limbs since 2 months and gangrene in left toes since 2weeks. CT angiogram revealed infra renal aortic occlusion with small left kidney due to left renal artery occlusion. Underwent infra renal aortic balloon angioplasty and stenting with balloon protection of right renal artery to prevent thrombus migration. Done in state scheme. #interventionalradiology #peripheralarterydisease #aorticinterventions #ISVIR #NRIAS, guntur
-
-
🔬 Scientific Director | Formulator🧪| 🥑 Expert in Ketogenic Dietary Therapies🍽️| Science Communicator 💡
The summation of these data suggest #ketogenic therapies may be particularly efficacious in right ventricular failure (RVF), and therefore future studies evaluating ketogenic interventions in human RVF are warranted. Full text: https://lnkd.in/gft7n98x #ketodiet #ketogenicdiet #keto #chetogenica #dietachetogenica
-
Director, Global Medical Affairs , Nephrology and Immunology at Otsuka Pharmaceutical Development & Commercialization
I am excited to be one of the authors on this comprehensive review https://lnkd.in/gcERpsr7 A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence
Now that we know blocking APRIL reduces proteinuria and stabilises eGFR in IgAN (https://lnkd.in/eNHE8puC), here is a paper on the underlying MoA: APRIL in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence https://lnkd.in/e2jYbEcr #mdpijcm via @JCM_MDPI
A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence
mdpi.com
